Tag: ADC
Risvutatug Rezetecan Demonstrates Overall Survival Benefit Over Topotecan in Relapsed Small...
Interim results from the pivotal Phase 3 ARTEMIS-008 trial (NCT06498479) show that risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, significantly reduced the risk of death...
From Withdrawal to Reapproval – Lessons From Gemtuzumab ozogamicin and Belantamab...
Two FDA-approved antibody-drug conjugates (ADCs)—gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth) and belantamab mafodotin (Blenrep®; GSK)—were withdrawn from the U.S. market after confirmatory trials failed to verify...
Sacituzumab Govitecan Plus Pembrolizumab Sustains Clinical Benefit Beyond First Progression in...
Triple-negative breast cancer (TNBC) remains one of the most challenging and most malignant subtypes of breast cancer to treat. TNBC represents a heterogeneous group...
The Evolving Role Of Antibody-Drug Conjugates In Solid Tumor Treatment: Current...
The Evolving Role Of Antibody-Drug Conjugates In Solid Tumor Treatment: Current Landscape And Future Directions
Lonza Expands ADC Capabilities with Strategic Investments and Integrated Technologies
Lonza Expands ADC Capabilities with Strategic Investments and Integrated Technologies
Wuxi and the Development of Antibody-Drug Conjugates: A Balanced Perspective
Wuxi and the Development of Antibody-Drug Conjugates: A Balanced Perspective
Datopotamab deruxtecan: First TROP2-Directed ADC Approved for First-Line Treatment of mTNBC...
Datopotamab deruxtecan: First TROP2-Directed ADC Approved for First-Line Treatment of mTNBC in Patients Ineligible for Immunotherapy
Degrader–Antibody Conjugates (DACs): Promises and Safety Questions
Degrader–antibody conjugates (DACs), including PROTAC- and molecular glue–based platforms, represent a paradigm shift beyond traditional cytotoxic antibody-drug conjugates (ADCs) in oncology. By leveraging antibody-mediated targeting with selective protein degradation, DACs promise both efficacy and specificity. However, these innovative modalities introduce a distinct and complex safety profile that requires careful consideration.
Antibody–Drug Conjugates in Cancer Therapy: Current Landscape, Advances, and Future Directions
Antibody–drug conjugates (ADCs) are a rapidly evolving class of targeted chemotherapeutics that combine the tumor selectivity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule payloads. Through rational linker design and optimized bioconjugation, ADCs have steadily advanced toward the goal of precision cancer therapy, achieving enhanced efficacy and reduced off-target toxicity. As of 2026, more than 15 ADCs have been approved globally for hematologic and solid tumors, with over 2,000 candidates in development and worldwide sales projected to exceed $16 billion
Mitigating Developability and Manufacturing Risks for Novel ADCs
Mitigating Developability and Manufacturing Risks for Novel ADCs
